Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire/Avexa Expand Agreement On HIV Candidate Apricitabine

This article was originally published in The Pink Sheet Daily

Executive Summary

Acquisition of North American marketing rights to the novel nucleoside reverse transcriptase inhibitor gives Australian biotech Avexa worldwide commercialization rights.

You may also be interested in...

Gilead Raises HIV Franchise Prices

GSK also initiates price increase for its HIV drugs.

Bristol Eyes HIV Portfolio Expansion

Agreement with Medivir and in-house development of two inhibitors could add to Bristol’s HIV stable.

Roche To Stop Selling Early HIV Drug HIVID

The company will continue to supply zalcitabine, one of the first nucleoside reverse transcriptase inhibitors, through the end of the year.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts